Vaccination of Older Adults in Portugal: Recommendations from the Geriatrics Study Group of the Portuguese Society of Internal Medicine

Authors

  • Paulo Ricardo Sousa Almeida Núcleo de Estudos de Geriatria. Sociedade Portuguesa de Medicina Interna. Lisboa. & Serviço de Medicina Interna. Unidade Local de Saúde de São João. Porto. & Faculdade de Medicina. Universidade do Porto. Porto. https://orcid.org/0000-0002-4879-559X
  • Gonçalo Sarmento Núcleo de Estudos de Geriatria. Sociedade Portuguesa de Medicina Interna. Lisboa. &Centro Geriátrico. Serviço de Medicina Interna. Unidade Local de Saúde de Entre Douro e Vouga. Santa Maria da Feira. https://orcid.org/0000-0003-2084-3665
  • Heidi Gruner Núcleo de Estudos de Geriatria. Sociedade Portuguesa de Medicina Interna. Lisboa. & Unidade de Geriatria. Serviço de Medicina 7.2. Unidade Local de Saúde de São José. Lisboa. & NOVA Medical School. Universidade NOVA de Lisboa. Lisboa. https://orcid.org/0000-0002-6045-1917
  • Rafaela Veríssimo Núcleo de Estudos de Geriatria. Sociedade Portuguesa de Medicina Interna. Lisboa. & Serviço de Medicina Interna. Unidade Local de Saúde de Gaia/Espinho. Vila Nova de Gaia. https://orcid.org/0000-0003-4102-6744
  • Sofia Duque Núcleo de Estudos de Geriatria. Sociedade Portuguesa de Medicina Interna. Lisboa. & Instituto de Medicina Preventiva e Saúde Pública. Faculdade de Medicina. Universidade de Lisboa. Lisboa. & Hospital CUF Descobertas. Lisboa. https://orcid.org/0000-0001-9273-5650

DOI:

https://doi.org/10.20344/amp.23786

Keywords:

Aged, Immunosenescence, Middle Aged, Portugal, Vaccination, Vaccines

Abstract

Older persons are more susceptible to infections and have a higher risk of serious complications, with a worse functional and vital prognosis. Vaccination is an effective strategy with a favorable safety profile for preventing infections and promoting healthy aging. In view of the clinical evidence and the vaccines available in Portugal in the first half of 2025, the Geriatrics Study Group of the Portuguese Society of Internal Medicine presents a proposal for vaccination of adults aged 65 years or older. The experts also point out the need to create a national lifelong vaccination program that includes older people to increase vaccination coverage and reduce the impact of infections in this population. Although the document focuses on people aged 65 years or older, vaccination against some diseases should start earlier. This article outlines five main recommendations: 1) Annual influenza and COVID-19 vaccination for all adults aged 50 years or older, with those aged 65 years or older receiving the high-dose trivalent influenza vaccine; 2) Respiratory syncytial virus vaccination for all adults aged 60 years or older and adults aged 18 - 59 years with risk factors, prioritizing people aged 75 years or older and those aged 50 years or older with risk factors; 3) Pneumococcal vaccination with the 20-valent or 21-valent pneumococcal conjugate vaccine for all adults aged 50 years or older and adults aged 18 - 49 years with risk factors; 4) Herpes zoster vaccination with the recombinant vaccine for all adults aged 50 years or older and adults aged 18 - 49 years at high risk of herpes zoster; 5) From the age of 65 years, booster vaccination against tetanus, diphtheria and pertussis every 10 years.

Downloads

Download data is not yet available.

References

Eurostat. Healthy life years statistics. 2024. [consultado 2025 jul 28]. Disponível em: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Healthy_life_years_statistics#Healthy_life_years_at_birth.

Eurostat. Population structure and ageing. 2025. [consultado 2025 jul 28]. Disponível em: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing.

Wagner A, Weinberger B. Vaccines to prevent infectious diseases in the older population: immunological challenges and future perspectives. Front Immunol. 2020;11:717.

Allen JC, Toapanta FR, Chen W, Tennant SM. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine. 2020;38:8264-72.

Kwetkat A, Heppner HJ. Comorbidities in the elderly and their possible influence on vaccine response. Interdiscip Top Gerontol Geriatr. 2020:43:73-85.

Esme M, Topeli A, Yavuz BB, Akova M. Infections in the elderly critically-ill patients. Front Med. 2019;6:118.

Burke M, Rowe T. Vaccinations in older adults. Clin Geriatr Med. 2018;34:131-43.

Sociedad Española de Geriatría y Gerontología. Recomendaciones de vacunación para adultos y mayores 2024-2025. 2025. [consultado 2025 jul 28]. Disponível em: https://www.segg.es/pdfViewer/web/viewer.asp?archivo=vacunacion2024-2025.

El Banhawi H, Chowdhury S, Neri M, Radu P, Hodgson S, Bell E, et al. Socio-economic value of adult immunisation programmes. 2024. [consultado 2025 jul 28]. Disponível em: https://www.ohe.org/publications/the-socio-economic-value-of-adult-immunisation-programmes/.

Direção-Geral da Saúde. Norma N.o 18/2020 de 27/09/2020. Programa nacional de vacinação 2020. 2020. [consultado 2025 jul 28]. Disponível em: https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-0182020-de-27092020-pdf.aspx.

Direção-Geral da Saúde. Norma N.o 13/2024 de 19/12/2024. Atualização da estratégia de vacinação pneumocócica – programa nacional de vacinação e grupos de risco. 2024. [consultado 2025 jul 28]. Disponível em: https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-0132024-de-19122024-atualizacao-da-estrategia-de-vacinacao-pneumococica-programa-nacional-de-vacinacao-e-grupos-de-risco-pdf.aspx.

Direção-Geral da Saúde. Norma N.o 07/2024 de 04/09/2024, atualizada a 07/03/2025. Campanha de vacinação sazonal contra a gripe: outono-inverno 2024-2025. 2025. [consultado 2025 jul 28]. Disponível em: https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-072024-de-04092024-atualizada-a-07032025-campanha-de-vacinacao-sazonal-contra-a-gripe-outono-inverno-2024-2025-pdf.aspx.

Direção-Geral da Saúde. Norma N.o 08/2024 de 05/09/2024, atualizada a 13/12/2024. Estratégia de vacinação contra a COVID-19. 2024. [consultado 2025 jul 28]. Disponível em: https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-082024-de-05092024-atualizada-a-13122024-estrategia-de-vacinacao-contra-a-covid-19-pdf.aspx.

Froes F, Carmo M, Lopes H, Bizouard G, Gomes C, Martins M, et al. Excess hospitalizations and mortality associated with seasonal influenza in Portugal, 2008–2018. BMC Infect Dis. 2022;22:726.

position paper from the Portuguese Society of Pulmonology, the Portuguese Society of Cardiology, the Portuguese Society of Diabetology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Geriatrics and Gerontology, and the Study Group of Geriatrics of the Portuguese Society of Internal Medicine. Pulmonology. 2024;30:422-36.

Infarmed. Efluelda tetra: resumo das características do medicamento. 2025. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Infarmed. Fluarix tetra: resumo das características do medicamento. 2025. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Infarmed. Influvac tetra: resumo das características do medicamento. 2025. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Infarmed. Vaxigrip tetra: resumo das características do medicamento. 2025. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Johansen ND, Modin D, Nealon J, Samson S, Salamand C, Loiacono MM, et al. A pragmatic randomized feasibility trial of influenza vaccines. NEJM Evid. 2023;2:EVIDoa2200206.

World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. 2024. [consultado 2025 jul 28]. Disponível em: https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2024-2025/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season.pdf?sfvrsn=2e9d2194_7&download=true.

Infarmed. Fluarix: resumo das características do medicamento. 2025. [consultado 2025 jul 28 jul]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Infarmed. Influvac: resumo das características do medicamento. 2025. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Infarmed. Vaxigrip: resumo das características do medicamento. 2025. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Infarmed. Efluelda: resumo das características do medicamento. 2025. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

European Medicines Agency. Fluad: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/fluad-epar-product-information_pt.pdf.

European Medicines Agency. Flucelvax: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/flucelvax-epar-product-information_pt.pdf.

Centers for Disease Control and Prevention. Influenza (Flu) - ACIP recommendations summary. 2024. [consultado 2025 jul 28]. Disponível em: https://www.cdc.gov/flu/hcp/acip/index.html.

Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older. 2025. [consultado 2025 jul 28]. Disponível em: https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/adult/adult-combined-schedule.pdf.

Instituto Nacional de Saúde Doutor Ricardo Jorge. Boletim de vigilância epidemiológica da gripe e outros vírus respiratórios - época 2024/2025 - semana 21 | 19 a 25 maio. 2025. [consultado 2025 jul 28]. Disponível em: https://www.insa.min-saude.pt/wp-content/uploads/2025/05/S21_2025.pdf.

Centers for Disease Control and Prevention. Underlying conditions and the higher risk for severe COVID-19. 2025. [consultado 2025 jul 28]. Disponível em: https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html.

European Medicines Agency. Comirnaty: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf.

European Medicines Agency. Spikevax: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/spikevax-epar-product-information_pt.pdf.

European Medicines Agency. Kostaive: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/kostaive-epar-product-information_pt.pdf.

European Medicines Agency. Bimervax: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/bimervax-epar-product-information_pt.pdf.

European Medicines Agency. Nuvaxovid: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/nuvaxovid-epar-product-information_pt.pdf.

Wyffels V, Kariburyo F, Gavart S, Fleischhackl R, Yuce H. A real-world analysis of patient characteristics and predictors of hospitalization among us medicare beneficiaries with respiratory syncytial virus infection. Adv Ther. 2020;37:1203-17.

Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. J Infect Dis. 2020;222:1298-310.

Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023;21:734-49.

Maggi S, Veronese N, Burgio M, Cammarata G, Ciuppa ME, Ciriminna S, et al. Rate of hospitalizations and mortality of respiratory syncytial virus infection compared to influenza in older people: a systematic review and meta-analysis. Vaccines. 2022;10:2092.

Lee N, Lui GC, Wong KT, Li TC, Tse EC, Chan JY, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57:1069-77.

Fonseca MJ, Reeves R, Pliakas T, Lopes R, Simão P, Coelho A, et al. Clinical and economic burden of respiratory syncytial virus among adults hospitalized with acute respiratory infections in Portugal. Poster apresentado no International RSV Symposium 2025, 12-15 mar; 2025; Iguazu, Brasil.

Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, Fischer TK, Egeskov-Cavling AM, Bøås H, et al. Estimation of the number of respiratory syncytial virus–associated hospitalizations in adults in the European Union. J Infect Dis. 2023;228:1539-48.

European Medicines Agency. mRESVIA: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/mresvia-epar-product-information_pt.pdf.

European Medicines Agency. Arexvy: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/arexvy-epar-product-information_pt.pdf.

European Medicines Agency. Abrysvo: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/abrysvo-epar-product-information_pt.pdf.

Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, et al. The efficacy of a single dose of the respiratory syncytial virus prefusion F protein vaccine in adults ≥60 years of age over 3 RSV seasons. Poster 3391 apresentado no CHEST 2024, 6-9 out; 2024; Boston, EUA.

Walsh EE, Pérez Marc G, Falsey AR, Jiang Q, Eiras D, Patton M, et al. RENOIR trial — RSVpreF vaccine efficacy over two seasons. N Engl J Med. 2024;391:1459-60.

Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA, Klein NP, et al. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024;404:1547-59.

Surie D, Self WH, Zhu Y, Yuengling KA, Johnson CA, Grijalva CG, et al. RSV vaccine effectiveness against hospitalization among US adults 60 years and older. JAMA. 2024;332:1105.

Tartof SY, Aliabadi N, Goodwin G, Slezak J, Hong V, Ackerson B, et al. Estimated vaccine effectiveness for respiratory syncytial virus–related lower respiratory tract disease. JAMA Netw Open. 2024;7:e2450832.

Alfaro T, Froes F, Vicente C, Costa R, Gavina C, Baptista R, et al. Respiratory syncytial virus vaccination in older adults and patients with chronic disorders: a position paper from the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine. Pulmonology. 2025;31:2451456.

Attaianese F, Guiducci S, Trapani S, Barbati F, Lodi L, Indolfi G, et al. Reshaping our knowledge: advancements in understanding the immune response to human respiratory syncytial virus. Pathogens. 2023;12:1118.

Adult Immunization Board. RSV specific topic: need for revaccination? When and how to organize it?. 2025. [consultado 2025 jul 28]. Disponível em: https://www.adultimmunizationboard.org/wp-content/uploads/2025/05/RSV-Specific-topic-Need-for-revaccination-When-and-how-to-organize-it.pdf.

European Centre for Disease Prevention and Control. Factsheet for health professionals about pneumococcal disease. 2023. [consultado 2025 jul 28]. Disponível em: https://www.ecdc.europa.eu/en/pneumococcal-disease/facts.

Grupo de Doenças Respiratórias da Associação Portuguesa de Medicina Geral e Familiar (GRESP). A doença pneumocócica e recomendações para a vacinação antipneumocócica na população adulta (≥18 anos). 2022. [consultado 2025 jul 28]. Disponível em: https://gresp.pt/ficheiros/recursos/folhetos/recomendacoes-gresp-vacinacao-anti-pneumococica.pdf.

Horácio AN, Diamantino-Miranda J, Aguiar SI, Ramirez M, Melo-Cristino J, the Portuguese Group for the Study of Streptococcal Infections. The majority of adult pneumococcal invasive infections in portugal are still potentially vaccine preventable in spite of significant declines of serotypes 1 and 5. PLoS ONE. 2013;8:e73704.

Hespanhol V, Bárbara C. Pneumonia mortality, comorbidities matter? Pulmonology. 2020;26:123-9.

European Medicines Agency. Prevenar 13: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/prevenar-13-epar-product-information_pt.pdf.

European Medicines Agency. Vaxneuvance: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/vaxneuvance-epar-product-information_pt.pdf.

European Medicines Agency. Prevenar 20: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/prevenar-20-epar-product-information_pt.pdf.

European Medicines Agency. Capvaxive: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/capvaxive-epar-product-information_pt.pdf.

Infarmed. Pneumovax 23: resumo das características do medicamento. 2022. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Vadlamudi NK, Parhar K, Altre Malana KL, Kang A, Marra F. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: a systematic review and meta-analysis. Vaccine. 2019;37:1021-9.

Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged ≥18 years. Clin Infect Dis. 2022;75:390-8.

Costa R, Costa R. Prevenção da doença pneumocócica no adulto nos cuidados de saúde primários: perspetivas futuras. Rev Port Clínica Geral. 2023;39:601-8.

Silva-Costa C, Gomes-Silva J, Teodoro I, Ramirez M, Melo-Cristino J, on behalf of the Portuguese Group for the Study of Streptococcal Infections. Invasive Pneumococcal Disease in Adults in Portugal: the importance of serotypes 8 and 3 (2015–2018). Microorganisms. 2021;9:1016.

Silva-Costa C, Gomes-Silva J, Santos A, Ramirez M, Melo-Cristino J, The Portuguese Group for the Study of Streptococcal Infections. Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children. Front Public Health. 2023;11:1279656.

Kobayashi M, Leidner AJ, Gierke R, Xing W, Accorsi E, Moro P, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the advisory committee on immunization practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74:1-8.

Cannon K, Elder C, Young M, Scott DA, Scully IL, Baugher G, et al. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. Vaccine. 2021;39:7494-502.

UK Health Security Agency. Immunisation against infectious disease - the green book. Chapter 25 - pneumococcal. 2023. [consultado 2025 jul 28]. Disponível em: https://assets.publishing.service.gov.uk/media/64d68d6edd15ff000d278019/Green_Book_Chapter_25_Pneumococcal_27_7_23.pdf.

Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.

Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7:ofaa005.

Direção-Geral da Saúde. Avaliação do programa nacional de vacinação - 2o inquérito serológico nacional portugal continental 2001–2002. 2004. [consultado 2025 jul 28]. Disponível em: https://www.dgs.pt/upload/membro.id/ficheiros/i009552.pdf.

Silva F, Castanheira RC, Zarkadoulas E, Figueira D, Bulhosa C, Borges M, et al. Landscape of herpes zoster infections in Portugal. Poster apresentado no Encontro de Outono 2024 da APMGF, 21-23 nov; 2024; Fátima, Portugal.

Silva F, Zarkadoulas E, Castanheira R, Castro O, Costa J, Silva Miguel L, et al. Burden of hospitalization related to adult herpes zoster infection in portugal. Poster EE443 apresentado no ISPOR-EU 2023, 12-15 nov; 2023; Copenhaga, Dinamarca.

European Medicines Agency. Shingrix: EPAR - product information. 2025. [consultado 2025 jul 28]. Disponível em: https://www.ema.europa.eu/pt/documents/product-information/shingrix-epar-product-information_pt.pdf.

Duque S, Marinho A, Almeida P, Marques Pereira R, Buzaco R. Recomendações para a vacinação contra o herpes zoster: documento de consenso da Sociedade Portuguesa de Medicina Interna e da Associação Portuguesa de Medicina Geral e Familiar. Med Interna. 2023;30:180-91.

Infomed. Detalhes do medicamento: zostavax. 2025. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

American Academy of Ophthalmology. Recommendations for herpes zoster vaccine for patients 50 years of age and older. Ophthalmology. 2018;125:1813-6.

Brandon D, Kimmel M, Kuriyakose SO, Kostanyan L, Mesaros N. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults. Vaccine. 2018;36:6325-33.

Pool V, Tomovici A, Johnson DR, Greenberg DP, Decker MD. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. Vaccine. 2018;36:2282-7.

Infarmed. Boostrix: resumo das características do medicamento. 2023. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Infarmed. Triaxis: resumo das características do medicamento. 2022. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Infarmed. D.T. vax adulto: resumo das características do medicamento. 2022. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

Infarmed. diTeBooster: Resumo das características do medicamento. 2024. [consultado 2025 jul 28]. Disponível em: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml.

European Centre for Disease Prevention and Control. Increase in pertussis cases in EU/EEA: infants under six months of age at the highest risk. 2024. [consultado 2025 jul 28]. Disponível em: https://www.ecdc.europa.eu/en/news-events/increase-pertussis-cases-eueea-infants-under-six-months-age-highest-risk.

Kardos P, Correia De Sousa J, Heininger U, Konstantopoulos A, MacIntyre CR, Middleton D, et al. Understanding the impact of adult pertussis and current approaches to vaccination: a narrative review and expert panel recommendations. Hum Vaccines Immunother. 2024;20:2324547.

Oliveira SM, Gonçalves-Pinho M, Freitas A, Guimarães H, Azevedo I. Trends and costs of pertussis hospitalizations in Portugal, 2000 to 2015: from 0 to 95 years old. Infect Dis. 2018;50:625-33.

Harrington L, Aris E, Bhavsar A, Jamet N, Akpo EI, Simeone JC, et al. Burden of pertussis in adults aged 50 years and older: a retrospective database study in England. Infect Dis Ther. 2023;12:1103-18.

European Centre for Disease Prevention and Control. Vaccine scheduler - pertussis: Recommended vaccinations. 2025. [consultado 2025 jul 28]. Disponível em: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=3&SelectedCountryIdByDisease=-1.

International Federation on Ageing and European Geriatric Medicine Society. Statement of action – supporting a life course approach within national immunization technical advisory groups (NITAGs). 2025. [consultado 2025 jul 28]. Disponível em: https://www.vaccines4life.com/wp-content/uploads/2025/01/IFA-EuGMS-Statement-1.pdf.

World Health Organization. Immunization agenda 2030. 2019. [consultado 2025 jul 28]. Disponível em: https://www.immunizationagenda2030.org.

Hou Y, Chen M, Bian Y, Hu Y, Chuan J, Zhong L, et al. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies. Npj Vaccines. 2024;9:77.

Published

2026-01-05

How to Cite

1.
Sousa Almeida PR, Sarmento G, Gruner H, Veríssimo R, Duque S. Vaccination of Older Adults in Portugal: Recommendations from the Geriatrics Study Group of the Portuguese Society of Internal Medicine. Acta Med Port [Internet]. 2026 Jan. 5 [cited 2026 Jan. 12];. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/23786

Issue

Section

Guidelines